Partnerships
Translating Cell-Specific Biology Into Differentiated Oncology Therapeutics
Cartography Biosciences combines proprietary single-cell atlases, primary human tissue sourcing, and integrated therapeutic engineering platforms to discover novel, highly specific tumor targets, and translate them into next-generation biologics. Our ATLAS and SUMMIT platforms power both our internal clinical pipeline and strategic collaborations with biopharma partners to advance first- and best-in-class oncology programs.
The Challenge
Limited Target Specificity Constrains Oncology Drug Development
A central challenge in oncology drug discovery is identifying targets that are highly specific to tumor cells while minimizing expression in healthy tissues. Many current therapies rely on broadly expressed lineage markers, leading to off-tumor toxicity, narrow therapeutic windows, and limited patient benefit. The lack of cell-specific biological insight has constrained the development of truly differentiated therapeutics and contributed to crowded pipelines focused on the same targets.
Target Identification and Validation
Cartography’s integrated ATLAS and SUMMIT platforms enable the discovery and prioritization of highly cell-specific tumor targets using large-scale single-cell atlases across healthy and tumor tissues. By providing deep insight into target expression, specificity, patient coverage, and potential liabilities at the individual cell level, the platforms de-risk novel and emerging targets. These biological insights are directly translated into therapeutic design, enabling the rational engineering of optimized single-target and multi-specific biologics guided by patient biology.
Analyzing and Improving Existing Targets
ATLAS and SUMMIT together enable the refinement of established oncology targets by resolving their true cell-type specificity and off-tumor expression profiles. Single-cell resolution data identifies safety liabilities and limitations of broadly expressed known targets, while SUMMIT applies multi-specific and logic-gated engineering strategies to improve tumor selectivity. This combined approach expands therapeutic windows and enables previously constrained targets to be advanced in more differentiated, safer therapeutic formats.
Developing Optimized Therapeutic Molecules
By integrating quantitative target biology with programmable therapeutic engineering, Cartography’s platforms drive the development of next-generation biologics optimized for efficacy, safety, and developability. ATLAS informs molecular design through insights into antigen density, tissue accessibility, and patient stratification, while SUMMIT systematically tunes molecular architecture, affinity, and functional performance. Together, they enable the creation of highly differentiated T-cell engagers and multi-specific therapeutics tailored to real patient biology.
Our Current Partnerships
Strategic Collaborations Advancing Novel Target Discovery
Cartography has established strategic discovery partnerships with leading biopharma organizations to advance novel oncology targets and therapeutic programs using our ATLAS and SUMMIT platforms. Our collaborations with Gilead and Pfizer focus on enabling next-generation biologics across multiple indications by leveraging our integrated discovery engine and proprietary single cell atlases to uncover highly specific novel targets and multi-specific target combinations with strong translational potential.
Together, these collaborations demonstrate the ability of Cartography’s platform to generate differentiated biological insights while continuing to power the advancement of our internal clinical pipeline.
Contact Us
Let’s Explore Collaboration Opportunities
If you are interested in partnering to advance novel targets, therapeutic programs, or platform-based discovery, we would welcome the opportunity to connect.
